Skip to main content
. Author manuscript; available in PMC: 2024 Mar 15.
Published in final edited form as: Clin Cancer Res. 2023 Sep 15;29(18):3603–3611. doi: 10.1158/1078-0432.CCR-23-0536

Table 1.

Patient Characteristics N = 12 (%)

Gender
 Female 5 (41.7)
 Male 7 (58.3)
Median (range) age in years 51 (Range 33–78)
Eastern Cooperative Oncology Group performance status
 0 2 (16.7)
 1 9 (75)
 2 1 (8.3)
Race
 White 8 (66.7)
 Asian 4 (33.3)
Diagnosis
 Small cell lung cancer 3 (25)
 Neuroendocrine prostate cancer 2 (16.7)
 Colorectal cancer 2 (16.7)
 Pancreatic cancer 2 (16.7)
 Neuroendocrine carcinoma of unknown primary 2 (16.7)
 Adrenocortical carcinoma 1 (8.3)
Type of prior therapy
 Chemotherapy 12 (100)
 Topoisomerase I inhibitor 5 (41.7)
 Immunotherapy 7 (58.3)
No. of prior systemic treatment
 1 2 (16.7)
 2 4 (33.3)
 3 3 (25)
 4 1 (8.3)
 >4 2 (16.7)